Chronic active Epstein-Barr virus infection involving gastrointestinal tract mimicking inflammatory bowel disease

Weijia Xu 1, Xiaoyun Jiang 1, Jiajie Chen 1, Qiqi Mao 1, Xianguang Zhao 1, Xu Sun 2, Liang Zhong 2 and Lan Rong 2*

Abstract

Background: Chronic active Epstein-Barr virus infection (CAEBV) is a rare disease, which is difficult to be differentiated from inflammatory bowel disease (IBD). To cause the attention, we present twelve cases of CAEBV in immunocompetent patients with gastrointestinal tract involvement.

Methods: Twelve patients who fulfilled the diagnostic criteria of CAEBV were enrolled in this retrospective study. The control group was consisted of twenty-four IBD patients with EBV-DNA value increased in peripheral blood. The clinicopathologic and endoscopic characteristics were reviewed and analyzed.

Results: The major clinical presentations of CAEBV patients were intermittent fever (100%), hepatomegaly/splenomegaly (58%), lymphadenopathy (50%), diarrhea (50%) and hematochezia (50%). Compared with IBD patients, the incidence of intermittent fever and increased level of ferritin were significantly higher among CAEBV patients. The median values for EBV detected in peripheral blood were significantly higher in CAEBV group (1.42*10^6 copies/μg) than in IBD group (3.2*10^3 copies/μg, p<0.05). The main endoscopic findings of CAEBV included multifocal or isolated, irregular, multiform ulcers and diffuse inflammation, lacking of typical cobblestone appearance. Ten patients died within 5 years of disease onset. The average survival time is 21 months.

Conclusions: Symptoms such as intermittent fever, increased level of ferritin and atypical endoscopic findings could be a sign for CAEBV. Early detections of EBV-DNA in serum and EBV-encoded small nuclear RNA (EBER) by in situ hybridization in intestinal tissue are essential for differential diagnosis between CAEBV and IBD.

Keywords: Inflammatory bowel disease, Epstein-Barr virus, Chronic active Epstein-Barr virus infection, Differential diagnosis

Background

Epstein-Barr virus (EBV) infections are usually acquired during childhood or adolescence. After primary infection, Epstein-Barr virus normally establishes a permanent latent state in B lymphocytes of immunocompetent hosts [1]. In western countries, EBV usually infects B cells. While in Asia, the disease sometimes involves T or NK cells, which relates with poor prognosis [2, 3]. Under some circumstances, target cells infected by Epstein-Barr virus expand and cause persistent or recurrent symptoms. This leads to a wide range of lymphoproliferative disorders, including posttransplant lymphoproliferative disease, Hodgkin or non-Hodgkin lymphoma and chronic active Epstein-Barr virus infection (CAEBV) [4].

Horwitz et al. [5] first described cases with high IgG antibody titers against EBV-replicating antigens which manifested as persistent or intermittent high fever and lymphadenopathy. In 2005, Joan Robinson [6] reported a
case with chronic active Epstein-Barr virus infection who presented with an inflammatory bowel disease (IBD) -like symptom. Many studies have reported the presence of Epstein-Barr virus in colonic mucosa of IBD patients [7, 8], including latent without any systematic symptoms and acute but self-limited infection. Due to the similar symptoms, it is a clinical challenge to discern whether the severity of symptoms is attributed to chronic Epstein-Barr virus infection, or the exacerbation of IBD. Misdiagnosis of CAEBV and IBD may cause delay in treatment, so it is significantly important to make the accurate diagnosis at patients’ first encounter.

Chronic active Epstein-Barr virus infection with gastrointestinal tract involvement is rather rare and is often misdiagnosed. The case reports in immunocompetent individuals are sporadic. Our study retrospectively collected twelve cases of CAEBV involving gastrointestinal tract and summarized the clinical manifestations, endoscopic, pathological features and prognosis of them.

**Methods**

**Patients**

From 2013 June to 2019 June, twenty-five patients who were diagnosed with gastrointestinal lesions with a positive result of Epstein-Barr virus testing on colonic mucosa were reviewed. Thirteen were excluded because of malignant tumor, acute infection or enteritis without systemic symptoms. The rest twelve patients who fulfilled the diagnostic criteria of CAEBV [4, 9] were retrospectively enrolled in our study. The inclusion criteria were as followed, 1) persistent or recurring infectious mononucleosis-like symptom, including fever, hepatosplenomegaly and lymphadenopathy, 2) Unusual pattern of anti-EBV antibodies, and/or detection of high EBV-DNA load in peripheral blood or affected tissues, 3) chronic illness which cannot be explained by other known disease processes at diagnosis.

Twenty-four patients were retrospectively enrolled as control group. The inclusion criteria were as followed, 1) confirmed IBD diagnosis based on clinical, endoscopic and histological features, 2) a positive result of EBV-DNA in peripheral blood.

Clinical manifestations, demographic, laboratory, endoscopic, pathological findings and follow-up information were acquired from chart reviewing.

**Quantitation of EBV-DNA and EBER detection by in situ hybridization**

Whole blood obtained from patients was centrifuged and separated into plasma and cell fractions. A quantitative real-time PCR assay was performed. The amount of EBV-DNA was calculated as viral DNA copies per milliliter blood. Mucosa for EBV-encoded small nuclear RNA (EBER) detection was biopsied from inflamed tissues. It was fixed by formalin and embedded in paraffin blocks. In situ hybridization (ISH) was performed according to the manufacturer’s instructions with EBER ISH Kit (ZSGB-BIO, Ltd., Beijing, China). The 4-μm-thick sections were transferred to pretreated slides and stored at 37 °C overnight. Then, slides were deparaffinized with xylene for 10 min and rehydrated with anhydrous alcohol for 5 min. After being washed with distilled water and dried, slides were digested by gastric enzyme for 30 min. The slides were incubated at 37 °C overnight with hybridization solution containing the EBER-probes and then washed with phosphate buffer saline. The anti-biotin antibody was applied. The slides were then counterstained with hematoxylin, mounted, and viewed with a standard light microscope.

EBER-positive staining was recognized as a brown color seen in the nucleus of cells. A known EBV-positive nasopharyngeal carcinoma was used as a positive control.

**Statistical analysis**

Baseline demographic and disease features are presented by using descriptive statistics. Continuous variables were described as median, while categorical variables were expressed as counts and percentages, with all range. Student’s t tests were used to compare continuous variables. A P value below 0.05 was considered statistically significant. Statistical analysis was conducted by SPSS version 16.0.

**Results**

Among the twelve patients who were diagnosed CAEBV with gastrointestinal tract involvement, eleven were males and one was female with a median age of 50 (range, 24–72). None of them had a history of transplantation, HIV infection or exposure to immunosuppressants. Among control group, sixteen were males and eight were females with a median age of 45 (range, 21–70). In control group, eleven were diagnosed Crohn disease (CD), while thirteen were diagnosed ulcerative colitis (UC).

**Clinical features**

The clinical features of all CAEBV patients and control group are summarized in Table 1. Gastrointestinal symptoms such as vomiting, diarrhea, abdominal pain and hematochezia were presented in all patients. The systemic symptoms were more often observed in CAEBV patients, including intermittent fever (100%), hepatomegaly/splenomegaly (58%) and lymphadenopathy (50%). Compared to control group, the incidence of
intermittent fever was significantly higher among CAEBV patients (p<0.05).

Laboratorial findings
The laboratory findings of both CAEBV patients and control group are summarized in Table 2. Blood examination showed increased levels of platelet, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) both in CAEBV patients and control group, while level of ferritin in CAEBV patients increased significantly (p<0.05). Positive results of Epstein-Barr virus DNA in peripheral blood were detected in all CAEBV patients (10/10, 100%). Two did not complete the test) and all control group patients (24/24, 100%). The median values for Epstein-Barr virus were significantly higher in CAEBV patients (1.42*10^6 copies/mL) compared to control group (3.2*10^3 copies/mL) (p<0.05). Clinical data of all enrolled CAEBV patients are summarized in Table 3.

Endoscopic features
Endoscopic manifestations of enrolled CAEBV patients are summarized in Table 4. The most frequently affected sites were colon (10/12), followed by small intestine (6/12) and stomach (1/12). Colon and small intestine were involved together in five cases. Six cases displayed profound and irregular ulcer with clear boundary, about 1.5–3.0 cm in diameter. Two cases displayed diffusely distributed, numerous shallow and small ulcers with inflammation. One case presented rigidity of intestinal wall and remarkable lymphangiectasia. One case showed a solitary longitudinal ulcer with clear boundary in jejunum. No cobblestone appearance was observed in all twelve cases (Fig. 1).

Table 1 Clinical symptoms of CAEBV group and control group

| Symptom            | CAEBV (n=12) | Control (n=24) | p-Value |
|--------------------|--------------|---------------|---------|
| Diarrhea           | 6 (50%)      | 18 (75%)      | >0.05   |
| Abdominal pain     | 4 (33%)      | 18 (75%)      | >0.05   |
| Vomiting           | 3 (25%)      | 0             | >0.05   |
| Hematochezia       | 6 (50%)      | 13 (54%)      | >0.05   |
| Intermittent fever | 12 (100%)    | 3 (13%)       | <0.05   |
| Hepatomegaly/Splenomegaly | 7 (58%) | 5 (21%) | >0.05 |
| Lymphadenopathy    | 6 (50%)      | 4 (17%)       | >0.05   |

Table 2 Laboratory index of CAEBV group and control group

| Index                | CAEBV (n=12) | Control (n=24) | p-Value |
|----------------------|--------------|----------------|---------|
| Increased PLT        | 59% (7/12)   | 45% (11/24)    | >0.05   |
| Increased ESR        | 67% (8/12)   | 63% (15/24)    | >0.05   |
| Increased CRP        | 100% (12/12) | 45% (11/24)    | >0.05   |
| Increased Fe protein | 100% (12/12) | 8% (2/24)      | f0.05   |

Pathological findings
In all CAEBV patients, chronic mucositis and erosion with clusters of lymphocytes infiltrating were observed and lymphocytes infiltrate into the submucosa and muscular layer occasionally. All the infiltrating lymphocytes exhibited polyclonal proliferation instead of monoclonal proliferation. The samples subjected to immunohistochemical staining were positive or partially positive for CD3, CD4 or CD56, which were consistent with EBV-associated T cell or NK cell lymphoproliferative disease. No granulomas were observed (Fig. 2). We had two patients went through surgeries because of intestinal perforation. In both surgical specimens, transmural inflammation and aggregation of lymphocytes were observed.

The results of in situ hybridization for EBER were all positive in CAEBV patients. More EBER-positive lymphocytes were identified in surgical sample. The positive lymphocytes distributed unevenly and were mainly observed near the ulcers or lymphocyte-rich regions.

Prognosis
Up to 2019 June, ten patients in CAEBV group died within 5 years of disease onset. The common direct cause of death included hemorrhage, disseminated intravascular coagulation and hemophagocytic syndrome. The average survival time is 21 months. One of the alive patients is under hemopoietic stem cell transplantation.

Discussion
In this study, we report twelve cases of CAEBV with gastrointestinal tract involvement and compare the clinicopathologic characteristics of them with IBD patients who have latent EBV infection. The results reveal some similarities between CAEBV and IBD, such as gastrointestinal symptoms and increased level of ESR and CRP. Involvement of other organs, such as enlargement of liver, spleen, and lymph nodes, is more often observed in CAEBV patients. If the lesions are only located in gastrointestinal tract, the differential diagnosis could be very difficult. We identify some characteristics, including intermittent fever, extremely high level of ferritin and atypical endoscopic manifestations, which could provide some evidence to avoid misdiagnosis.

The enrolled CAEBV patients commonly presented with gastrointestinal symptoms of diarrhea and abdominal pain, clinically mimicking IBD. Some of the distinctions between clinical presentations of CAEBV and IBD are as follows: 1) The abdominal pain in CAEBV is more severe, hardly relieves spontaneously. 2) Fever, especially inexplicable intermittent high fever, is more common in CAEBV patients. 3) The level of ferritin increases drastically in CAEBV, which correlates with EBV infection.
In our study, the endoscopic features included inflammations and ulcers of variable morphological characteristics. The ulcers are irregular and multiform, which could be profound or superficial, isolated or multifocal. The signs are distinct from typical cobblestone appearance observed in CD and a uniform and continuous inflammation observed in UC [10]. Liu et al. [11] have reported some CAEBV cases with numerous shallow, small, and irregular ulcers in both colon and small intestine. These signs were observed in some of our patients. Since few articles have reported endoscopic findings in CAEBV with gastrointestinal tract involvement, our findings may provide some information for the awareness of the rare disease.

The results of EBV-DNA quantitation analysis in peripheral blood were positive in all enrolled patients, but higher in CAEBV group. The median values were $1.42 \times 10^6$ copies/mL in CAEBV, compared to $3.2 \times 10^3$ copies/mL in IBD, suggesting the disease is linked to viral replication. On the contrary, Epstein-Barr virus antibody tests are less useful because the antibody profile can mimic a latent EBV infection in IBD patient.

### Table 3: Clinical characteristics of 12 CAEBV patients

| NO | Sex | Age ranges | Course of disease | Symptoms | EBV-DNA (copies/ml) | Surgery | Medicine | Prognosis |
|----|-----|------------|------------------|----------|---------------------|---------|----------|-----------|
| 1  | 1   | 20–30      | 3 years          | Fever, hematochezia | $4.34 \times 10^6$ | NO       | Steroids, antibiotics and antiviral-drugs | Dead     |
| 2  | 1   | 50–60      | 3 months         | Fever, vomiting, diarrhea | NA     | NO       | Steroids, antibiotics and thalidomide | Dead     |
| 3  | 1   | 40–50      | 4 months         | Fever, hematochezia | NA     | NO       | Steroids, antiviral-drugs and immunoglobulin | Dead     |
| 4  | 1   | 40–50      | 3 years          | Fever, vomiting, diarrhea | $4.0 \times 10^7$ | NO       | Steroids and immunoglobulin | Dead     |
| 5  | 1   | 30–40      | 2 months         | Fever, hematochezia | $1.14 \times 10^7$ | NO       | Steroids and antivirus | Dead     |
| 6  | 1   | 40–50      | 2 years          | Fever, hematochezia | $1.22 \times 10^5$ | YES      | Steroids | Dead     |
| 7  | 1   | 20–30      | 1 year           | Fever, diarrhea | $1.54 \times 10^6$ | NO       | Steroids | Dead     |
| 8  | 2   | 30–40      | 3 years          | Fever, vomiting, abdominal pain, diarrhea | $3.12 \times 10^5$ | NO       | Steroids, antiviral-drugs and immunoglobulin | Dead     |
| 9  | 1   | 40–50      | 17 months        | Fever, abdominal pain | $1.09 \times 10^3$ | YES      | Steroids, antiviral-drugs | Dead     |
| 10 | 1   | 40–50      | 2 months         | Fever, abdominal pain, hematochezia | $1.29 \times 10^6$ | NO       | Steroids | Dead     |
| 11 | 1   | 50–60      | 1 month          | Fever, abdominal pain, diarrhea | $1.85 \times 10^4$ | NO       | Steroids and hematopoietic stem cell transplantation | Survive |
| 12 | 1   | 70–80      | 3 months         | Fever, diarrhea, hematochezia | $1.63 \times 10^6$ | NO       | Steroids and antibiotics | Dead     |

In consideration for patients’ anonymity, we amend sex from “male” and “female” to “1” and “2” for publication.

### Table 4: Endoscopic manifestations of 12 CAEBV patients

| NO  | Involved location     | Segmental Distribution | profound ulcer | shallow ulcer | Boundary mucosal hyperplasia | mucosal erosion | Rigidity of intestinal wall | Stenosis |
|-----|-----------------------|------------------------|----------------|---------------|-----------------------------|----------------|----------------------------|----------|
| 1   | jejunum, terminal ileum and colon | no yes no | yes clear no yes yes yes no |
| 2   | ileum and colon       | yes yes (3 cm)         | no clear yes yes no no |
| 3   | ileum and colon       | no no yes | yes clear yes yes no no |
| 4   | jejunum, ileum and colon | yes yes (2 cm) | yes clear yes yes no no |
| 5   | stomach and colon     | yes yes (2 cm)         | yes clear yes yes no no |
| 6   | ileum                 | yes yes (3 cm)         | yes clear yes yes no no |
| 7   | colon                 | yes yes (1 cm)         | no clear no yes no no |
| 8   | colon                 | yes no no             | no clear no no no no |
| 9   | ileum                 | yes yes no            | yes clear no yes no no |
| 10  | colon                 | yes yes (1.5 cm)       | no clear yes yes no no |
| 11  | colon                 | yes no yes            | yes clear no no no no |
| 12  | colon                 | yes no yes            | yes clear no no no no |
Kimura et al. [12] have analyzed thirty CAEBV patients, and discovered not all patients had high titers of EBV-specific antibodies, but all patients had high viral loads in their peripheral blood. He recommended that viral load detected in peripheral blood mononuclear cell (PBMC) could be a criterion for disease diagnosis and an indicator of therapeutic efficacy. Yamamoto et al. [13] reported patients with CAEBV infection had cell-free EBV DNA in plasma, suggesting the presence of EBV DNA in plasma may have significance for the diagnosis of CAEBV infection. Among the twelve patients, we have two patients tested for EBV DNA in plasma, the results

---

**Fig. 1** Endoscopic findings of CAEBV patients. **a** isolated giant ulcer in the ileocecum (case 2); **b** solitary longitudinal ulcer with clear rim in jejunum (case 4); **c** Diffuse inflammation in ileocecum (case 8); **d** multifocal irregular ulcers in the ascending colon (case 10)

---

**Fig. 2** Histopathological findings of CAEBV patient (case 11). **a** Haematoxylin and eosin (H&E) staining showed Lymphoid cells distributed in muscular layer and serosa; **b, c** Immunohistochemical staining revealed positive expressions of CD4+ (**b**), CD20+ (**c**); **d** In situ hybridization indicating positive EBER
were 8.9*10^2 copies/mL and 6.3*10^3 copies/mL respectively. With the development of laboratory technology, more patients will be tested in PBMC and plasma. The combined application of EBV DNA tested in PBMC and plasma could be useful for CAEBV diagnosis.

At present, the golden standard for demonstrating Epstein-Barr virus infection in lesion is in situ hybridization for EBER. However, the criteria regarding percentage of EBER-positive cells for the definition of EBV infection is still not established. In the previously published articles, the threshold differs from 10 to 20% [14, 15]. Liu et al. [11] have reported eleven cases among which all surgery samples had more than 100 EBV+ cells/HPF, and the biopsy samples were more than 30 EBV+ cells/HPF. Our study showed the similar result, which is correspondent to specimen quantity. It should be noticed that we also had one case with 30 EBV+ cells/HPF in control group. As the patient had no sign of fever, hepatomegaly or other systemic symptoms and his result of EBV-DNA in peripheral blood was negative, we considered this patient clear of chronic active Epstein-Barr virus infection. Therefore, single evidence of EBER-positive is not enough for diagnosis of CAEBV. Other information, including symptoms, laboratorial results, endoscopic findings and histopathological manifestations should be combined to consider. This is consistent with previous published article [16, 17].

Chronic active Epstein-Barr virus infection often results in poor prognosis. A large cohort study [18] in Japan reported that 43% of patients died during follow-up periods that ranged from 5 months to 12 years after the onset of severe CAEBV infection. Risk factors for death include late onset of disease (onset age>8 years), thrombocytopenia and EBV infection on T cell. Successful allogeneic, hematopoietic stem cell transplantation was reported [19]. However, the transplantation constitutes a substantial risk to recipient patients. The post-transplantation mortality rate for a series of Japanese patients was 50% [18]. In our study, ten patients died within 5 years of disease onset. One of the alive patients is now under stem cell transplantation.

In 1999, Yanai et al. [8] applied in situ hybridization technique to detect the presence of EBER-positive cells in intestinal mucosa of IBD patients. Previous researches showed the data about EBV infection in colonic mucosa of IBD patients varied from 45.5 to 81.0% [16, 20–22]. Li et al. [23] recently completed a cross-sectional study in China, they found that EBV was detectable in 33 out of 99 IBD patients (33.3%). EBV prevalence in colonic mucosa may contributes to high clinical disease activity in IBD patients. Takeda et al. [24] reported a UC patient with EBV detected in rectum and terminal ileum. The overall clinical picture in this patient was compatible with UC. With standard treatment for UC, his condition improved and the colonoscopy revealed improvement.

It's reported that long-term administration of corticosteroids and immunosuppressant therapy may activate EBV reactivation [25]. For the patients under treatment of corticosteroids, immunosuppressant or biologics, we monitor EBV activity regularly. However, there is no internationally accepted standard about the testing method, interval or the critical value. We had a patient once tested 100 times higher of EBV-DNA in his peripheral blood after 2 months biologics therapy. The patient suspended biologics and turned to mesalazine, but his symptoms relapsed. As the level of EBV-DNA decreased, he restarted the biologics with caution after 6 months rest. The level of EBV-DNA remained stable and symptoms relieved as well. Although we all know monitoring is important, it is still hard to tell on what point to terminate the therapy for patients' best interest.

Conclusions

Chronic active Epstein-Barr virus infection involving gastrointestinal tract is rare and very difficult to differentiate from IBD due to overlapping symptoms and endoscopic findings. Our study illustrates the need to maintain high suspicion for CAEBV among patients with intermittent febrile illnesses, extremely high level of ferritin and atypical endoscopic findings. Blood test for EBV-DNA and repeated biopsy for EBER by in situ hybridization should be performed to gain more information to confirm the diagnosis.

Abbreviations

CAEBV: Chronic active Epstein-Barr virus infection; IBD: Inflammatory bowel disease; EBV: Epstein-Barr virus; EBER: EBV-encoded small nuclear RNA; ISH: In situ hybridization; CD: Crohn disease; UC: Ulcerative colitis; ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein; PBMC: Peripheral blood mononuclear cell

Acknowledgments

The authors are grateful to all participants for their cooperation.

Authors’ contributions

All authors contributed to this work. WJ X collected, analyzed the data and drafted the manuscript. XY J, JJ C, QQ M, XG Z and X S took care of the patients. L Z and L R designed and supervised the study. L R acted as corresponding author. All authors approved the final version of the manuscript.

Funding

This work was funded by HuaShan North Hospital Research Initiation Fund. [Grant Number: HSBY20160009]. The funder was involved in study design but had no role in data acquisition, analysis and writing the manuscript.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Ethics approval and consent to participate
The study described was approved by the Huashan Hospital ethics committee. All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All participants were informed in writing and verbally of the procedures and purpose of this study, and signed written informed consent forms.

Consent for publication
Not applicable.

Competing interests
The authors declare no editorial or financial conflicts of interests.

Author details
1. Department of Gastroenterology, Huashan Hospital (North), Fudan University, Shanghai, China. 2. Department of Gastroenterology, Huashan Hospital, Fudan University, Shanghai, China.

Received: 28 January 2020 Accepted: 22 July 2020
Published online: 05 August 2020

References
1. Taylor GS, Long HM, Brooks JM, et al. The immunology of Epstein-Barr virus-induced disease. Annu Rev Immunol. 2015;33:787–821.
2. Kimura H, Hoshino Y, Hara S, et al. Differences between T cell-type and natural killer cell-type chronic active Epstein-Barr virus infection. J Infect Dis. 2005;191:531–9.
3. Cohen J, Jaffe ES, Dale JK, et al. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood. 2011;117:5835–49.
4. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.
5. Horwitz CA, Henle W, Henle G, et al. Clinical evaluation of patients with infectious mononucleosis and development of antibodies to the R component of the Epstein-Barr virus-induced early antigen complex. Am J Med. 1975;58:330–8.
6. Roth DE, Jones A, Smith L, et al. Severe chronic active Epstein-Barr virus infection mimicking steroid-dependent inflammatory bowel disease. Pediatr Infect Dis J. 2005;24:261–4.
7. Wakefield AJ, Fox JD, Sawyerr AM, et al. Detection of herpesvirus DNA in the large intestine of patients with ulcerative colitis and Crohn’s disease using the nested polymerase chain reaction. J Med Virol. 1999;58:330.
8. Yanai H, Shimizu N, Nagasaki S, et al. Epstein-Barr virus infection of the colon with inflammatory bowel disease. Am J Gastroenterol. 1999;94:1582–6.
9. Okano M, Kawa K, Kimura H, et al. Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection. Am J Hematol. 2005;80:64–9.
10. Nikolaus S, Schreiber S. Diagnostics of inflammatory bowel disease. Gastroenterology. 2007;133:1670–89.
11. Liu R, Wang M, Zhang L, et al. The clinicopathologic features of chronic active Epstein-Barr virus infective enteritis. Mod Pathol. 2019;32:387–95.
12. Kimura H, Hoshino Y, Kanegane H, et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood. 2001;98:280–6.
13. Yamamoto M, Kimura H, Hironaka T, et al. Detection and quantification of virus DNA in plasma of patients with Epstein-Barr virus-associated diseases. J Clin Microbiol. 1995;33:1765–8.
14. Chang ST, Lu YH, Lu CL, et al. Epstein-Barr virus is rarely associated with diffuse large B cell lymphoma in Taiwan and carries a trend for a shorter median survival time. J Clin Pathol. 2014;67:326–32.
15. Nissen LH, Nagtegaal ID, de Jong DJ, et al. Epstein-Barr virus in inflammatory bowel disease: the spectrum of intestinal lymphoproliferative disorders. J Crohns Colitis. 2015;9:398–403.
16. Ryan JL, Shen Y, Morgan DR, et al. Epstein-Barr virus infection is common in inflamed gastrointestinal mucosa. Dig Dis Sci. 2012;57:1887–98.
17. Bertalot G, Villanacci V, Gamegna M, et al. Evidence of Epstein-Barr virus infection in ulcerative colitis. Dig Liver Dis. 2001;33:551–8.
18. Kimura H, Morishima T, Kanegane H, et al. Prognostic factors for chronic active Epstein-Barr virus infection. J Infect Dis. 2003;187:527–33.
19. Okamura T, Hatsuoka Y, Arai H, et al. Blood stem-cell transplantation for chronic active Epstein-Barr virus with lymphoproliferation. Lancet. 2000;356:223–4.
20. Speiker T, Herbst H. Distribution and phenotype of Epstein-Barr virus-infected cells in inflammatory bowel disease. Am J Pathol. 2000;157:51–7.
21. Van Kuiningen HJ, Poulin M, Garmentia AE, et al. Search for evidence of recurring or persistent viruses in Crohn’s disease. APMS. 2007;115:962–8.
22. Ciccioppioppo R, Racca F, Paolucci S, et al. Human cytomegalovirus and Epstein-Barr virus infection in inflammatory bowel disease: need for mucosal viral load measurement. World J Gastroenterol. 2015;21:1915–26.
23. Li X, Chen N, You P, et al. The status of Epstein-Barr virus infection in intestinal mucosa of Chinese patients with inflammatory bowel disease. Digestion. 2019;99:126–32.
24. Takeda Y, Takada K, Togashi H, et al. Demonstration of Epstein-Barr virus localized in the colonic and ileal mucosa of a patient with ulcerative colitis. Gastrointest Endosc. 2000;51:205–9.
25. Ciccioppioppo JT, Kielis-Glaser JK, Malarkey WB, et al. Autonomic and glucocorticoid associations with the steady-state expression of latent Epstein-Barr virus. Horm Behav. 2002;42:32–41.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.